Array BioPharma (NASDAQ:ARRY)

bull and bear

Top Analyst Upgrades and Downgrades: CBOE, Comcast, GW Pharma, Hormel, Vonage, Wells Fargo and Many More

Stocks were indicated higher on Tuesday after Monday's first presidential debate. Despite a bull market that is seven and a half years old, and despite high valuations, investors are still willing ...
Read Full Story »
analysis

4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate

Monday is kicking off a very important week in the markets, with earnings season on the horizon and the first presidential debate later in the evening. Biotech and pharmaceutical companies ...
Read Full Story »
cash

10 Analyst Stock Picks Under $10 for Massive Upside

24/7 Wall St. is constantly on the hunt for undiscovered opportunities and hidden value in the financial markets. Even in hard times there are always some opportunities that can be ...
Read Full Story »
FDA_logo

Key FDA Decisions and Trial Results Coming in the Next 2 Months

U.S. Food and Drug Administration (FDA) rulings and the results from clinical trials have proven time and again that they can make or break companies. The biotech and pharmaceutical ...
Read Full Story »
upside

5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside

We are coming into the fall and the third quarter, after a surprisingly solid push from the markets over the summer. Analysts may say it isn’t fundamentally sound but that does not ...
Read Full Story »
FDA_logo

8 Major FDA Decisions and Trial Results to Watch for in September

Pharmaceutical and biotech companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount to a great amount ...
Read Full Story »
Doctor, Health (pulse) copy

Array BioPharma Continues Its Silent Rally With Mid-Stage Trial Win

Shares of Array BioPharma Inc. (NASDAQ: ARRY) saw a handy gain in Tuesdays session following the announcement of mid-stage results from its cardiomyopathy trial. These trial results were presented at ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Harley-Davidson, HP, KeyCorp, KLA-Tencor, Netflix, Square, T-Mobile and More

Stocks were indicated higher on Monday, but by such a small margin we would count it as a nondirectional move. The markets are still very close to all-time highs, and ...
Read Full Story »
hammered

Top 6 Companies That Destroyed Shareholders Last Week

The broad markets are continuing to hit all-time highs as the market is shifting gears out of the earnings season. Despite all the positive sentiment in the market, quite a ...
Read Full Story »
graph

3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential

Needless to say, the biotech world has had a very difficult year. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have suffered ...
Read Full Story »
clinical trials

Why Array Is Making a Run

Array BioPharma Inc. (NASDAQ: ARRY) is watching its shares make a handy gain on Friday after making a key U.S. Food and Drug Administration (FDA) submission. The company announced the ...
Read Full Story »
Female patient on gurney

Array BioPharma Rallies on Late-Stage Win

Array BioPharma Inc. (NASDAQ: ARRY) led the bulls early on Monday on news of a positive late-stage clinical trial. The company reported top-line results from the ongoing Phase 3 clinical ...
Read Full Story »
Comfortable hospital bed

Key Insider Buying in Twitter, Level 3, Sears, MBIA and More

While the late summer doldrums are here, the insider action since the end of the second-quarter earnings season is hardly dull. Just like last week, executives and 10% owners are ...
Read Full Story »
Biotechnology word cloud

4 Speculative Biotechs With Huge Analyst Targets

Investors have been in love with the speculative biotech sector for years now. If there is one group of stocks that can produce returns of 100%, 200% or even ten-baggers, ...
Read Full Story »
Money background. Close-up.

What Is Really Driving Array Higher

Array BioPharma Inc. (NASDAQ: ARRY) released is fiscal third-quarter earnings before the markets opened Monday. The company reported a net loss of $0.11 per share on $6.6 million in revenue for the ...
Read Full Story »